Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 9, 2000, Pages 2333-2340

  Aviles, P ^a   Falcoz, C ^a   San Roman, R ^a   Gargallo Viola, D ^a  

^a GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GM 237354;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; FUNGICIDAL ACTIVITY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; CANDIDA ALBICANS; CANDIDIASIS; DISEASE MODELS, ANIMAL; INDENES; MALE; MICE; MICROBIAL SENSITIVITY TESTS; STATISTICS; TREATMENT OUTCOME;

EID: 0033844811     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.9.2333-2340.2000     Document Type: Article

References (30)

1. Guidelines for the welfare of animals in rodent protection tests. A report from the Rodent Test Working Party
2. Correlation between in vitro and in vivo activity of antifungal agents against Candida species
3. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model
4. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
5. Evolutionary biology, animal behavior, fourth-dimensional space, and the raison d'etre of drug metabolism and pharmacokinetics
6. First-time in human dose selection: Allometric thoughts and perspectives
7. Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice
8. PK/PD parameters: Rationale for antibacterial dosing of mice and men
9. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans
10. Sordarins: A new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts
11. Role of pharmacokinetics in the outcome of infections
12. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model
13. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model
14. Experimental infection with Streptococcus pneumoniae in mice: Correlation of in vitro activity and pharmacokinetic parameters with in vivo effect of 14 cephalosporins
15. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mouse
16. Fluconazole treatment of Candida albicans infection in mice: Does in vitro susceptibility predict in vivo response?
17. Sordarins: In vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi
18. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species
19. Comparative antibiotic dose-effect relations at several dosing intervals in routine pneumonitis and thigh-infection models
20. Pharmacodynamics of fluconazole in a routine model of systemic candidiasis
21. Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics
22. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion
23. Is continuous infusion of beta-lactam antibiotics worthwhile? - Efficacy and pharmacokinetic considerations
24. Bactericidal activity of cephalosporins in an in vitro model simulating serum levels
25. Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo
26. Evaluation of quinolones in experimental animal models of infections
27. Mathematical examination of dual individualization principles. I. Relationships between AUC above MIC and area under the inhibitory curve of cefmenoxime, ciprofloxacin, and tobramycin
28. Optimal dosage of beta-lactam antibiotics: Time above the MIC and inoculum effect
29. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B
30. Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. Albicans strains